Medicare Finalizes Coverage for Transplant Molecular Testing
The new policy affirms coverage for surveillance testing to detect organ rejection in kidney, heart, and lung transplant patients.
Read MorePosted by CLP Edit Staff | Jul 21, 2026 | Transfusion & Transplantation Tests |
The new policy affirms coverage for surveillance testing to detect organ rejection in kidney, heart, and lung transplant patients.
Read MorePosted by CLP Edit Staff | Jul 16, 2026 | Molecular Diagnostics |
Behavioral Diagnostics and Versiti Clinical Trial Solutions have partnered to provide epigenetic assays for objective smoking and alcohol exposure screening in clinical trials, aiming to improve participant risk assessment and data reliability.
Read MorePosted by CLP Edit Staff | Jul 6, 2026 | Cancer, Company News, Molecular Diagnostics |
The test utilizes genomic sequencing and AI to identify biological signals associated with early-stage disease.
Read MorePosted by CLP Edit Staff | Jun 30, 2026 | Company News, Womens Health |
The patent covers a gene-expression profiling method designed to identify patients most likely to respond to the investigational therapy stenoparib through 2042.
Read MorePosted by CLP Edit Staff | Jun 26, 2026 | Cancer, Company News |
GRAIL secured $110 million in equity financing from Samsung affiliates to support U.S. regulatory efforts and expand its Galleri multi-cancer early detection test into Asian markets, the companies announced.
Read More